Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
11.41
-0.76 (-6.24%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions.
It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biopharma Inc.
| Country | United States |
| Founded | 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Jerel Banks |
Contact Details
Address: 3940 Trust Way Hayward, California 94545 United States | |
| Phone | 510 780 0819 |
| Website | benitec.com |
Stock Details
| Ticker Symbol | BNTC |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001552795 |
| CUSIP Number | 08205P100 |
| ISIN Number | US08205P2092 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jerel A. Banks M.D., Ph.D. | Executive Chairman and Chief Executive Officer |
| Megan Joan Boston B.Com., C.A. | Executive Director |
| Dr. Michael Graham | Head of Discovery and Founding Scientist |
| Dr. Claudia Kloth Ph.D. | Senior Vice President of Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2020 | 15-12B | Securities registration termination |
| Apr 16, 2020 | EFFECT | Notice of Effectiveness |
| Apr 16, 2020 | EFFECT | Notice of Effectiveness |
| Apr 15, 2020 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 15, 2020 | POS AM | Post-Effective amendments for registration statement |
| Apr 15, 2020 | POS AM | Post-Effective amendments for registration statement |
| Apr 15, 2020 | 6-K | Report of foreign issuer |
| Apr 14, 2020 | 25 | Filing |
| Apr 14, 2020 | 25-NSE | Filing |
| Apr 3, 2020 | 6-K | Report of foreign issuer |